keyword
MENU ▼
Read by QxMD icon Read
search

Primary mediastinal large B cell lymphoma

keyword
https://www.readbyqxmd.com/read/28935521/a-study-of-the-dosimetric-characteristics-between-different-fixed-field-imrt-and-vmat-in-early-stage-primary-mediastinal-b-cell-lymphoma
#1
Li-Ming Xu, Ming-Lei Kang, Bo Jiang, Qing-Feng Liu, Ye-Xiong Li
This analysis was designed to compare dosimetric parameters among different fixed-field intensity-modulated radiation therapy (IMRT) solutions and volumetric-modulated arc therapy (VMAT) to identify which can achieve the lowest risk of organs at risk (OARs) and treatment delivery efficiently. A total of 16 patients (8 male and 8 female) with early-stage primary mediastinal large B-cell lymphoma (PMBCL) were enrolled with planned gross tumor volume (PGTV) 45 Gy and planning target volume (PTV) 40 Gy. Four different plans were generated: 5-, 7, 9-field IMRT, and VMAT...
September 18, 2017: Medical Dosimetry: Official Journal of the American Association of Medical Dosimetrists
https://www.readbyqxmd.com/read/28932613/primary-pulmonary-lymphoma-presenting-with-superior-vena-cava-syndrome-in-a-young-female
#2
Divya Salhan, Prakash Verma, Tun Win Naing, Ebad Ur Rehman, Saroj Kandel, Danillo Enriquez, Joseph Quist, Frances Schmidt
Primary Pulmonary Diffuse Large B Cell Lymphoma (PPDLBCL) is an extremely rare entity, which exhibits an aggressive behavior by compressing local blood vessels. It represents only 0.04% of all lymphoma cases and is extremely rare in young age. We present a case of a primary pulmonary lymphoma with superior vena cava syndrome (SVCS) in a young female. 27-year-old African American female presented with fever, cough, and facial puffiness for 2 weeks and unintentional weight loss. Chest examination showed decreased breath sounds and dullness on percussion on right side...
2017: Case Reports in Pulmonology
https://www.readbyqxmd.com/read/28921451/distribution-of-malignant-lymphomas-in-the-anterior-mediastinum-a-single-institution-study-of-76-cases-in-japan-1997-2016
#3
Akiko Miyagi Maeshima, Hirokazu Taniguchi, Tomotaka Suzuki, Sayako Yuda, Kosuke Toyoda, Nobuhiko Yamauchi, Shinichi Makita, Suguru Fukuhara, Wataru Munakata, Dai Maruyama, Yukio Kobayashi, Kensei Tobinai
We analyzed the distribution of tumors and lymphomas of the anterior mediastinum diagnosed between 1997 and 2016 at the National Cancer Center Hospital, Japan. The median age of 283 patients with anterior mediastinal tumors was 48 (range 6-84) years, and 143 (51%) were male. The incidence of tumors was as follows: thymoma, 34%; thymic carcinoma, 16%; primary mediastinal large B-cell lymphoma (PMBL), 13%; germ cell tumors, 10%; classical Hodgkin lymphoma (CHL), 9%; thymic cyst, 7%; metastatic tumors, 3%; T lymphoblastic leukemia/lymphoma (T-LBL), 2%; other lymphomas, 3%; and others, 3%...
September 18, 2017: International Journal of Hematology
https://www.readbyqxmd.com/read/28910870/-primary-mediastinal-large-b-cell-lymphoma-a-clinicopathologic-study-of-27-cases
#4
Q Y Shi, X Feng, H Chen, H H Ma, Z F Lu, Q L Shi, X J Zhou, Q Shen
Objective: To study the clinicopathologic characteristics and diagnostic criteria of primary mediastinal B-cell lymphoma (PMBL), and to distinguish PMBL from classic Hodgkin lymphoma(CHL) and systemic diffuse large B-cell lymphoma(DLBCL). Methods: The clinical features, histologic findings, results of immunohistochemical study and prgnosis in 27 PMBL cases were analyzed, with review of literature. Results: The age of patients ranged from 19 to 82 years (median age 34 years). All cases were located in the mediastinum and frequently accompanied by superior vein cava syndrome...
September 8, 2017: Zhonghua Bing Li Xue za Zhi Chinese Journal of Pathology
https://www.readbyqxmd.com/read/28877074/gata3-immunohistochemical-staining-in-hodgkin-lymphoma-diagnostic-utility-in-differentiating-classic-hodgkin-lymphoma-from-nodular-lymphocyte-predominant-hodgkin-lymphoma-and-other-mimicking-entities
#5
Brie Kezlarian, Mohammad Alhyari, Girish Venkataraman, Kristin Karner, Kedar V Inamdar, Madhu P Menon
BACKGROUND: Classic Hodgkin lymphoma (CHL) and nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) are clinically distinct entities, with different prognostic and treatment implications. In addition, several large B-cell lymphomas and some T-cell lymphomas can mimic CHL. Differentiating these entities from CHL is crucial for ensuring appropriate therapy. GATA3 is a T-cell transcription factor involved in T-cell maturation and has been previously shown to be overexpressed in CHL cells via gene expression profiling...
September 4, 2017: Applied Immunohistochemistry & Molecular Morphology: AIMM
https://www.readbyqxmd.com/read/28851661/j-chain-and-myocyte-enhancer-factor-2b-are-useful-in-differentiating-classical-hodgkin-lymphoma-from-nodular-lymphocyte-predominant-hodgkin-lymphoma-and-primary-mediastinal-large-b-cell-lymphoma
#6
Erika M Moore, Steven H Swerdlow, Sarah E Gibson
Although most classical Hodgkin lymphomas (CHL) are easily distinguished from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) and primary mediastinal large B-cell lymphoma (PMBL), cases with significant CD20 expression cause diagnostic confusion. Although the absence of OCT-2 and BOB.1 are useful in these circumstances, a variable proportion of CHL are positive for these antigens. We investigated the utility of J chain and MEF2B in the diagnosis of CHL, NLPHL, PMBL, T-cell/histiocyte-rich large B-cell lymphoma (TCRLBL), and B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and CHL (BCLU, DLBCL/CHL) compared to OCT-2 and BOB...
August 26, 2017: Human Pathology
https://www.readbyqxmd.com/read/28798034/fdg-pet-ct-in-lymphoma-has-imaging-directed-personalized-medicine-become-a-reality
#7
Sally F Barrington, Peter Wm Johnson
Positron emission tomography with computed tomography (PET-CT) using (18)F- fluorodeoxyglucose (FDG) is an essential part of the management of patients with lymphoma. Efforts to standardize PET acquisition and reporting, including the five-point 'Deauville scale', have enabled PET to become a surrogate for treatment success/failure in common lymphoma subtypes. This review summarizes the key evidence from clinical trials that supports PET-directed personalized approaches in lymphoma. PET-guided therapy has improved outcomes in Hodgkin lymphoma, using less chemotherapy and more selective radiotherapy...
August 10, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28766543/-bone-marrow-involvement-in-primary-mediastinal-b-cell-lymphoma
#8
A U Magomedova, E A Fastova, A M Kovrigina, T N Obukhova, N I Skidan, Ya K Mangasarova, A I Vorobyev, S K Kravchenko
Primary mediastinal large B-cell lymphoma (PMBCL) is a distinct type of large B-cell lymphoma. In this type of the disease, the neoplastic process is located in the anterior and superior mediastinum, frequently with compression of the superior vena cava and with tumor invasion into the adjacent organs and tissues: the pericardium, lung, pleura, etc. Despite the fact that in PMBCL progression, there may be involvement of extranodal organs, such as the kidney, adrenal glands, liver, and central nervous system, bone marrow (BM) injury is generally absent...
2017: Terapevticheskiĭ Arkhiv
https://www.readbyqxmd.com/read/28732145/evaluation-of-primary-mediastinal-large-b-cell-lymphoma-by-flow-cytometry
#9
Sindhu Cherian, Jonathan R Fromm
BACKGROUND: Primary mediastinal large B cell lymphoma (PMLBCL) is a B cell non-Hodgkin lymphoma (B-NHL) that shows morphologic, immunophenotypic, and genetic similarities to classical Hodgkin lymphoma (CHL). We evaluated the neoplastic and reactive infiltrate of PMLBCL by flow cytometry (FC). METHODS: A total of 24 cases of PMLBCL were retrospectively characterized using FC combinations for B-NHL, T-NHL, and CHL. RESULTS: The CHL assay identified the neoplastic population (NP) in all cases, while the B-NHL assay identified the NP in 18 of 24 cases...
July 21, 2017: Cytometry. Part B, Clinical Cytometry
https://www.readbyqxmd.com/read/28722111/monoamine-oxidase-a-is-highly-expressed-in-classical-hodgkin-lymphoma
#10
Pei Chuan Li, Imran N Siddiqi, Anja Mottok, Eric Y Loo, Chieh Hsi Wu, Wendy Cozen, Christian Steidl, Jean Chen Shih
Monoamine oxidase A (MAOA) is a mitochondrial enzyme that catalyzes oxidative deamination of neurotransmitters and dietary amines and produces H2 O2 . It facilitates the progression of gliomas and prostate cancer, but its expression and functional relevance have not been studied in lymphoma. Here, we evaluated MAOA in 427 cases of Hodgkin and non-Hodgkin lymphoma and in a spectrum of reactive lymphoid tissues by immunohistochemistry on formalin-fixed, paraffin-embedded specimens. MAOA was expressed by Hodgkin Reed-Sternberg (HRS) cells in the majority of classical Hodgkin lymphomas (cHLs) (181/241; 75%), with 34...
October 2017: Journal of Pathology
https://www.readbyqxmd.com/read/28684378/utility-of-bone-marrow-biopsy-and-aspirate-for-staging-of-diffuse-large-b-cell-lymphoma-in-the-era-of-positron-emission-tomography-with-2-deoxy-2-fluorine-18-fluoro-deoxyglucose-integrated-with-computed-tomography
#11
Prakash Vishnu, Andrew Wingerson, Marie Lee, Margaret T Mandelson, David M Aboulafia
BACKGROUND: About one-third of patients with diffuse large B cell lymphoma (DLBCL) have lymphomatous bone marrow involvement (BMI) at the time of diagnosis, and bone marrow aspirate/biopsy (BMAB) is considered the gold standard to detect such involvement. [(18)F] fluorodeoxyglucose positron emission tomography combined with computed tomography (PET-CT), has become standard pretreatment imaging in DLBCL and may be a noninvasive alternative to BMAB to ascertain BMI. Prior studies have suggested that PET-CT scan may obviate the need for BMAB as a component for staging patients with newly diagnosed DLBCL, but this is not yet a standard of practice...
June 17, 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/28659618/an-oncogenic-axis-of-stat-mediated-batf3-upregulation-causing-myc-activity-in-classical-hodgkin-lymphoma-and-anaplastic-large-cell-lymphoma
#12
A Lollies, S Hartmann, M Schneider, T Bracht, A L Weiß, J Arnolds, L Klein-Hitpass, B Sitek, M-L Hansmann, R Küppers, M A Weniger
Classical Hodgkin lymphoma (cHL) and anaplastic large cell lymphoma (ALCL) feature high expression of activator protein-1 (AP-1) transcription factors, which regulate various physiological processes but also promote lymphomagenesis. The AP-1 factor basic leucine zipper transcription factor, ATF-like 3 (BATF3), is highly transcribed in cHL and ALCL; however, its functional importance in lymphomagenesis is unknown. Here we show that proto-typical CD30(+) lymphomas, namely cHL (21/30) and primary mediastinal B-cell lymphoma (8/9), but also CD30(+) diffuse large B-cell lymphoma (15/20) frequently express BATF3 protein...
June 29, 2017: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/28653407/clinical-heterogeneity-of-diffuse-large-b-cell-lymphoma-following-failure-of-front-line-immunochemotherapy
#13
Umar Farooq, Matthew J Maurer, Carrie A Thompson, Gita Thanarajasingam, David J Inwards, Ivana Micallef, William Macon, Sergei Syrbu, Tasha Lin, Yi Lin, Stephen M Ansell, Grzegorz S Nowakowski, Thomas M Habermann, James R Cerhan, Brian K Link
This study aimed to describe the patterns of care and outcomes of diffuse large B cell lymphoma (DLBCL) after failure of front line anthracycline-based immunochemotherapy (IC). Patients with newly diagnosed lymphoma were prospectively enrolled in Molecular Epidemiology Resource (MER) of the University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellzence. All DLBCL and primary mediastinal B-cell lymphoma (PMBL) patients treated with front-line anthracycline-based IC were followed for relapse...
June 27, 2017: British Journal of Haematology
https://www.readbyqxmd.com/read/28634685/poor-predictive-value-of-positive-interim-fdg-pet-ct-in-primary-mediastinal-large-b-cell-lymphoma
#14
Julien Lazarovici, Marie Terroir, Julia Arfi-Rouche, Jean-Marie Michot, Sacha Mussot, Valentina Florea, Maria-Rosa Ghigna, Peggy Dartigues, Cynthia Petrovanu, Alina Danu, Christophe Fermé, Vincent Ribrag, David Ghez
PURPOSE: Though commonly used to assess response to therapy, the prognostic value of interim FDG-PET/CT in Primary Mediastinal Large B-cell Lymphoma (PMBCL) is unclear. METHODS: We conducted a retrospective study on 36 consecutive patients treated at our institution for a PMBCL between 2006 and 2014. All patients with a positive interim FDG-PET/CT had undergone histological restaging consisting either in a surgical debulking of the residual lesion (15 patients) or a CT-guided core needle biopsy (two patients)...
June 21, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28620906/management-of-primary-mediastinal-b-cell-lymphoma-and-gray-zone-lymphoma
#15
Kieron Dunleavy
Primary mediastinal B-cell lymphoma is a distinct clinicopathologic entity that has a predilection for young women. It is clinically and molecularly different from other subtypes of diffuse large B-cell lymphoma and has a unique paradigm of management. While the cure rate for patients with primary mediastinal B-cell lymphoma is high, approaches have historically included mediastinal radiation; in moving therapeutics forward, strategies that obviate the need for radiation while maintaining high cure rates are critical...
June 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28490569/safety-and-tolerability-of-pembrolizumab-in-patients-with-relapsed-refractory-primary-mediastinal-large-b-cell-lymphoma
#16
MULTICENTER STUDY
Pier Luigi Zinzani, Vincent Ribrag, Craig H Moskowitz, Jean-Marie Michot, John Kuruvilla, Arun Balakumaran, Yayan Zhang, Sabine Chlosta, Margaret A Shipp, Philippe Armand
Treatment options for relapsed/refractory primary mediastinal large B-cell lymphoma (rrPMBCL) are limited, and prognosis is generally poor (overall response rate [ORR] 0% to 25%; 2-year overall survival 15%). PMBCL frequently involves PD-1 ligand overexpression, potentially making PMBCL particularly susceptible to PD-1 blockade. We evaluated safety and antitumor activity of pembrolizumab, an anti-PD-1 antibody, in rrPMBCL as part of the KEYNOTE-013 multicohort phase 1b trial. At time of data cutoff, 18 patients (median age 30 years; median 3 prior lines of therapy) had been enrolled and treated, of whom 17 were included in the efficacy analyses...
July 20, 2017: Blood
https://www.readbyqxmd.com/read/28485042/prognostic-models-for-primary-mediastinal-thymic-b-cell-lymphoma-derived-from-18-fdg-pet-ct-quantitative-parameters-in-the-international-extranodal-lymphoma-study-group-ielsg-26-study
#17
MULTICENTER STUDY
Luca Ceriani, Maurizio Martelli, Annarita Conconi, Pier L Zinzani, Andrés J M Ferreri, Barbara Botto, Caterina Stelitano, Manuel Gotti, Maria G Cabras, Luigi Rigacci, Luca Giovanella, Emanuele Zucca, Peter W M Johnson
The International Extranodal Lymphoma Study Group-26 study evaluated the prognostic role of 18-fluorodeoxyglucose positron-emission tomography (PET) in primary mediastinal large B-cell lymphoma. We assessed quantitative PET parameters at diagnosis and post-treatment in 100 patients. The end-of-therapy total lesion glycolysis (TLG) was the best individual outcome predictor, but the combination of baseline TLG and end-of-therapy visual analysis with Deauville Score (DS) showed a better positive predictive value...
August 2017: British Journal of Haematology
https://www.readbyqxmd.com/read/28415982/the-treatment-of-primary-mediastinal-large-b-cell-lymphoma-a-two-decades-monocentric-experience-with-98-patients
#18
Alessandro Broccoli, Beatrice Casadei, Vittorio Stefoni, Cinzia Pellegrini, Federica Quirini, Lorenzo Tonialini, Alice Morigi, Miriam Marangon, Lisa Argnani, Pier Luigi Zinzani
BACKGROUND: The purpose of this study is to investigate the most suitable first-line approach and the best combination treatment for primary mediastinal large B-cell lymphoma (PMLBCL) as they have been matter of debate for at least two decades. METHODS: Our single centre experience in the treatment of 98 de novo PMLBCL patients over the last 20 years is reviewed. All patients received MACOP-B chemotherapy. Thirty-seven received both rituximab and mediastinal radiotherapy; 30 were irradiated after chemotherapy, although not receiving rituximab and 20 received rituximab without radiotherapy consolidation...
April 17, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28373787/multimodality-imaging-evaluation-of-a-primary-cardiac-lymphoma
#19
Paolo Ciancarella, Armando Fusco, Daniele Citraro, Massimiliano Sperandio, Roberto Floris
Primary cardiac lymphoma is a rare form of non-Hodgkin lymphoma that involves the heart with extension to pericardium and great vessels. Prognosis is poor in the absence of a prompt diagnosis and adequate therapy. Differential diagnosis includes malignant neoplasms such as angiosarcoma or metastatic carcinoma and melanoma. Clinical manifestations may be heterogeneous. Multimodality imaging work-up represents the best method for tumor detection and evaluation of its size and extension: echocardiography, computed tomography, magnetic resonance imaging, and nuclear imaging are the best imaging tools...
April 2017: Journal of the Saudi Heart Association
https://www.readbyqxmd.com/read/28318892/primary-mediastinal-large-b-cell-lymphoma
#20
REVIEW
Maurizio Martelli, Andrés Ferreri, Alice Di Rocco, Michela Ansuinelli, Peter W M Johnson
Primary mediastinal large B-cell lymphoma (PMLBCL) is a distinct clinical and biological disease from other types of DLBCL. It is more frequent in young female and constitutes 6%-10% of all DLBCL. PMLBCL is characterized by a diffuse proliferation of medium to large B-cells associated with sclerosis. Molecular analysis shows it to be a distinct entity from other DLBCL. Rituximab CHOP/MACOP-B-like regimens followed by mediastinal radiotherapy (RT) were associated with a 5-years PFS of 75%-85%. More intensive regimens, as DA-EPOCH-R without mediastinal RT, have shown very promising results, but this therapeutic advance needs to be confirmed in further prospective trials...
May 2017: Critical Reviews in Oncology/hematology
keyword
keyword
81323
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"